Metformin
Metformin (Biguanide)
The longevity drug hiding in plain sight
Medical Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. Peptides discussed may be research compounds not approved for human use. Always consult a qualified healthcare provider before starting any peptide protocol. Read our full disclaimer →
Quick Reference
| Peptide Class | AMPK Activator / Longevity Drug |
| Half-Life | 4-9 hours |
| Administration | Oral |
| Typical Dosage | 500-1000mg daily (longevity); 500-2000mg daily (metabolic) |
| Cycle Length | Ongoing daily use |
| Evidence Level | Strong Human Clinical |
| Legal Status | Prescription only; available via telehealth |
| Approximate Cost | $10-40/month generic |
How Metformin Works
Activates AMPK to mimic caloric restriction, inhibit mTOR, and improve insulin sensitivity
Metformin inhibits Complex I of the mitochondrial respiratory chain, reducing ATP production and activating AMPK (the cellular energy sensor). AMPK activation mimics fasting — it inhibits mTOR, activates autophagy, improves insulin sensitivity, and reduces hepatic glucose output. These effects collectively reduce metabolic aging and inflammation.
Evidence Base
Preclinical Evidence
Extends lifespan in multiple animal models. Reduces cancer incidence and metabolic disease.
Human Evidence
Decades of safety data. TAME trial ongoing. Observational data shows reduced all-cause mortality.
Anecdotal Evidence
Users report improved energy, reduced appetite, and better metabolic lab values within weeks.
Key PubMed References:
Safety Profile
Side Effects
GI side effects (nausea, diarrhea) are common at initiation, especially with immediate-release formulations. Extended-release formulations significantly reduce GI side effects. Rare: B12 deficiency with long-term use (supplement recommended).
Contraindications
Renal impairment (eGFR <30). Iodinated contrast procedures (hold 48 hours before/after). Excessive alcohol use. Hepatic impairment.
PeptidePilot Assessment
Metformin is PeptidePilot's top recommendation for users over 40 with metabolic health and longevity as co-primary goals. Its unmatched safety record, low cost, and broad evidence base make it the most accessible longevity intervention available.
📊 10% of PeptidePilot users with metabolic health and longevity as co-primary concerns receive Metformin as their top match
Frequently Asked Questions
Explore More Peptides
The most researched healing peptide for joints, tendons, and gut tissue.
Systemic tissue repair and anti-inflammatory recovery for athletes and injury rehabilitation.
The cleanest growth hormone secretagogue for muscle growth, fat loss, and sleep quality.
Extended-release GHRH analogue that amplifies and sustains growth hormone pulses.
The clinically established GHRH analogue with the longest safety record in anti-aging medicine.
The most clinically validated peptide for weight loss and metabolic health.